Design and analysis of longitudinal trials of antimicrobial use at the end of life: to give or not to give?

Authors:
Juthani-Mehta M; Allore HG.

Journal:
Ther Adv Drug Saf

Publication Year: 2019

DOI:
10.1177/2042098618820210

PMCID:
PMC6378640

PMID:
30800269

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Adv Drug Saf

Abbreviation: Ther Adv Drug Saf

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass in…
Shaikh F; Wynne R; L Castelino R and 3 more (2024) - Transparency Score: 3/6
Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Eve…
Jiang T; Su H; Xu J and 9 more (2024) - Transparency Score: 3/6
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition betwe…
Sørensen CA; Jeffery L; Roelsgaard K and 4 more (2023) - Transparency Score: 3/6
Analysis of the nature and contributory factors of medication safety incidents following hospital d…
Alqenae FA; Steinke D; Carson-Stevens A and 1 more (2023) - Transparency Score: 3/6
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance u…
Altebainawi AF; Alfaraj LA; Alharbi AA and 2 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest statement: The authors declare that there is no conflict of interest. Dr Juthani-Mehta served as a consultant to Iterum Therapeutics."

Evidence found in paper:

"Funding: Funding was received from the US National Institute of Aging at the National Institutes of Health (R01 AG047891, P30 AG021342)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025